GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insur Regulatory News (SBRE)

Share Price Information for Sabre Insur (SBRE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 164.20
Bid: 164.60
Ask: 165.60
Change: -1.00 (-0.61%)
Spread: 1.00 (0.608%)
Open: 167.00
High: 167.00
Low: 164.20
Prev. Close: 165.20
SBRE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Oct 2018 07:00

RNS Number : 6525D
Sabre Insurance Group PLC
11 October 2018
 

11 October 2018

 

SABRE INSURANCE GROUP PLC

Trading Update

Sabre Insurance Group plc (the "Group", or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides a trading update for the nine months ending 30 September 2018.

Summary

· The Group continues its strategy of focusing on underwriting profitability over growth

· Superior underwriting performance, underpinned by strong claims experience in the period under review, supports the Group's continued expectation of delivering a FY 2018 combined ratio better than our mid-70%'s target and slightly higher than the FY 2017 combined ratio, which was 68.5%

· Strong organic capital generation supports the potential for an attractive full-year dividend with a solvency coverage ratio of 195%(1) as at the end of September, above our 140% - 160% target range

· Appropriate pricing actions taken to cover anticipated claims inflation, with GWP for the first nine months of the year remaining broadly flat year on year at £162.6m(1) (2017: £165.0m). The Group maintains its expectations for FY 2018 GWP to be in line with 2017

 

Geoff Carter, Chief Executive Officer, commented:

Throughout a period of strong competition in the UK motor insurance sector, we have continued to apply our core philosophy of focusing on underwriting profitability, with volume remaining an output rather than target.

As communicated earlier in the year, we have sought to cover anticipated claims inflation and will continue this focus throughout the rest of this year. Whilst premiums for Q3 2018 were slightly below a strong comparative period in Q3 2017, we remain confident that we will end the year with premium in-line with 2017.

Our absolute focus on profitability has yielded a strong underwriting result for the year to date and has allowed us to generate significant excess capital during the period under review. Having paid an interim dividend of 7.2 pence per share, the solvency capital ratio as at 30 September 2018 is at 195%, well above our target operating range of 140%-160%. This provides the Board the option to return surplus capital to shareholders following the full-year results, should the capital position improve further throughout the remainder of 2018. 

(1) Numerical information not subject to audit

 

 

Media enquiries

Tulchan Communications LLP

James Macey White, Roger Tejwani & David Ison

020 7353 4200

sabre@tulchangroup.com

 

Investor enquiries

Sabre Insurance Group plc

Adam Westwood

adam.westwood@sabre.co.uk

07776 649 119

 

LEI code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFFUFISFASELS
Date   Source Headline
1st May 202011:58 amRNSHolding(s) in Company
27th Apr 20207:00 amRNSNotice of AGM
24th Apr 202011:44 amRNSHolding(s) in Company
23rd Apr 20202:08 pmRNSDirector/PDMR Shareholding
22nd Apr 20207:00 amRNSHolding(s) in Company
20th Apr 20201:58 pmRNSDirector/PDMR Shareholding
16th Apr 20202:57 pmRNSDirector/PDMR Shareholding
7th Apr 20203:45 pmRNSDirector/PDMR Shareholding
7th Apr 202012:02 pmRNSPrice Monitoring Extension
7th Apr 20207:00 amRNSFinal Results
3rd Apr 20204:41 pmRNSSecond Price Monitoring Extn
3rd Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 202012:23 pmRNSNotification of Results Announcement Date
24th Mar 20207:00 amRNSDelay of Full Year results announcement
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:39 pmRNSPrice Monitoring Extension
19th Mar 202012:03 pmRNSPrice Monitoring Extension
18th Mar 20204:42 pmRNSSecond Price Monitoring Extn
18th Mar 20204:38 pmRNSPrice Monitoring Extension
18th Mar 202012:07 pmRNSSecond Price Monitoring Extn
18th Mar 202012:02 pmRNSPrice Monitoring Extension
11th Mar 202010:45 amRNSDirector/PDMR Shareholding
9th Mar 202012:07 pmRNSSecond Price Monitoring Extn
9th Mar 202012:02 pmRNSPrice Monitoring Extension
28th Feb 202010:14 amRNSDirector Declaration
11th Feb 20203:07 pmRNSDirector/PDMR Shareholding
13th Jan 20201:53 pmRNSDirector/PDMR Shareholding
3rd Jan 202012:02 pmRNSPrice Monitoring Extension
11th Dec 201911:41 amRNSDirector/PDMR Shareholding
22nd Nov 20198:50 amRNSHolding(s) in Company
12th Nov 20192:35 pmRNSDirector/PDMR Shareholding
6th Nov 20191:57 pmRNSHolding(s) in Company
22nd Oct 20194:55 pmRNSHolding(s) in Company
22nd Oct 20194:52 pmRNSHolding(s) in Company
15th Oct 201910:03 amRNSDirector/PDMR Shareholding
11th Oct 20193:12 pmRNSDirector/PDMR Shareholding
11th Oct 201910:58 amRNSDirector/PDMR Shareholding
10th Oct 20197:00 amRNSTrading Update
20th Sep 201911:14 amRNSDirector/PDMR Shareholding
11th Sep 201910:26 amRNSDirector/PDMR Shareholding
4th Sep 201910:57 amRNSHolding(s) in Company
13th Aug 201912:18 pmRNSDirector/PDMR Shareholding
9th Aug 201912:07 pmRNSSecond Price Monitoring Extn
9th Aug 201912:02 pmRNSPrice Monitoring Extension
31st Jul 20198:34 amRNSHolding(s) in Company
30th Jul 20197:00 amRNSHalf-year Report
11th Jul 20195:08 pmRNSDirector/PDMR Shareholding
29th May 20199:09 amRNSHolding(s) in Company
23rd May 201911:33 amRNSAGM Statement
23rd May 20197:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.